Caplin Steriles gets USFDA approval for Linezolid Injection, Infusion bags

Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Linezolid Injection 600mg/300mL (2mg/mL) Single-dose Infusion Bags, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) ZYVOX from Pfizer Inc.

Linezolid Injection is an anti-bacterial primarily used to treat serious bacterial infections, including pneumonia and skin infections, particularly those resistant to other antibiotics. According to IQVIATM (IMS Health), Linezolid Injection had US sales of approximately $23 million for the 12-month period ending October 2025.

Shares of Caplin Point Laboratories Limited was last trading in BSE at Rs. 1927.10 as compared to the previous close of Rs. 1963.05. The total number of shares traded during the day was 2234 in over 407 trades.

The stock hit an intraday high of Rs. 1963.85 and intraday low of 1900.00. The net turnover during the day was Rs. 4298369.00.

Source : Equity Bulls

Keywords

CaplinPointLaboratories INE475E01026 Pharmaceuticals CaplinSteriles USFDA Approval LinezolidInjection InfusionBags